DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for encephalomyelitis — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEncephalomyelitis maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for encephalomyelitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
FKBP prolyl isomerase 1A (FKBP1A) — FKBP1A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 4~{s},5~{r},6~{z},9~{s},10~{s},12~{e}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6I1S · 1.52 Å · ligand (4~{S},5~{R},6~{Z},9~{S},10~{S},12~{E})-16-(ethylamino)-4,5-dimethyl-9,10,18-tris(oxidanyl)-3-oxabicyclo[12.4.0]octadeca-1(14),6,12,15,17-pentaene-2,8-dione (E26). Experimental structure, not a prediction.
What the evidence adds up to
Two patients with acute disseminated encephalomyelitis deteriorated after standard high-dose methylprednisolone and then received intravenous immunoglobulin. Both showed dramatic clinical improvement and returned to their previous level of functioning. This is a 2000 report with a sample size of two, no control group, and no blinding.
A 2022 case report describes a 40-year-old woman with progressive ascending paralysis and MRI findings consistent with demyelination. She received high-dose steroids followed by a course of IVIG but showed no significant response and died. The authors note that during the pandemic, ADEM should be considered in patients with altered mentation, polyfocal neurological deficits, and a history of recent COVID-19 infection or SARS-CoV-2 vaccination.
A 2012 retrospective case series of six patients reports that five recovered completely with no recurrence on follow-up. The sixth patient’s outcome is not specified. The series does not describe which treatments were given or whether any patient failed therapy. The 2003 case report emphasises diagnostic difficulty but provides no treatment data. The 2001 abstract discusses experimental autoimmune encephalitis as a model but contains no human treatment results. The 2019 review summarises immunopathogenetic mechanisms and pathogenetic treatment but gives no new clinical data.
What is still missing: prospective trials with adequate sample size, standardised outcome measures, and stratification by disease severity or trigger (post-infectious, post-vaccination, idiopathic). No randomised controlled trial of IVIG versus placebo or versus steroids alone has been published for ADEM. The contradictory outcomes between the 2000 case pair and the 2022 fatal case highlight the need for systematic evidence rather than anecdotal reports. Funding for such trials remains absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurology · 2000 · 143 citations
Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin
AbstractAcute disseminated encephalomyelitis (ADEM) is a presumed immune-mediated, demyelinating disease of the CNS for which the standard treatment is high-dose steroids. We describe two patients with ADEM in whom treatment with IV methylprednisolone coincided with deterioration in their clinical status. They were subsequently treated with IV immunoglobulin and exhibited dramatic clinical improvement, with return to their previous level of functioning.
The Journal of Experimental Medicine · 2001 · 115 citations · open access
Myelin-Specific Cd8 T Cells in the Pathogenesis of Experimental Allergic Encephalitis and Multiple Sclerosis
AbstractExperimental autoimmune encephalomyelitis (EAE) serves as the prototypic model for T cell–mediated autoimmunity. EAE has striking similarities with the human disease acute disseminated encephalomyelitis, a complication seen with vaccination and after certain viral infections. EAE has been used as
International Journal of Clinical Practice · 2003 · 14 citations · open access
ACUTE DISSEMINATED ENCEPHALOMYELITIS: A RIDDLE WRAPPED IN A MYSTERY INSIDE AN ENIGMA
AbstractThe difficulties in establishing a diagnosis of acute disseminated encephalomyelitis (ADEM) are illustrated in this case report, which attempts to raise awareness of the condition among general physicians, since they are the practitioners most likely to see such acute neurological presentations. Clinical and investigative features which raise the index of suspicion for the diagnosis of ADEM are outlined.
Indian Journal of Critical Care Medicine · 2022 · 4 citations · open access
A Fatal Case of Acute Disseminated Encephalomyelitis: A Diagnosis to Ponder in Pandemic
AbstractA 40-year-old woman known hypertensive presented with progressive ascending paralysis. MRI T2W and FLAIR screening of the brain demonstrated swelling with altered signal in the visual cervical cord, medulla, and another juxtacortical lesion in the right temporal lobe with possibility of a demyelinating etiology. CSF testing did not identify a direct cerebral infection. High-dose steroids followed by a course of IVIG was administered but with no significant response. In these pandemic times, the patients who present with altered mentation and polyfocal neurological deficits and background history of recent COVID-19 infection or recipient of SARS-CoV-2 vaccine the diagnosis of acute disseminated encephalomyelitis (ADEM) should be considered likely. How to cite this article: Kumar A, Sabharwal P, Gupta P, Singh VK, Rao BK. A Fatal Case of Acute Disseminated Encephalomyelitis: A Diagnosis to Ponder in Pandemic. Indian J Crit Care Med 2022;26(4):518-520.
Siberian medical review · 2019 · 2 citations · open access
ACUTE DISSEMINATED ENCEPHALOMYELITIS
AbstractTh is review summarizes current ideas about such disease as acute disseminated encephalomyelitis.Epidemiology and immunopathogenetic mechanisms of acute brain demyelination development are studied in details.Th e aspects of diff erential diagnosis and pathogenetic treatment are shown.
Pediatric Oncall · 2012 · 0 citations · open access
Acute Disseminated Encephalomyelitis- Myriads of Presentation
AbstractThis retrospective case series of 6 patients illustrates various clinical presentations of acute disseminated encephalomyelitis (ADEM). The patients presented with acute onset of focal neurological deficit (3 patients), psychosis (1 patient) and ataxia (1 patient) and visual loss (1 patient). Magnetic Resonance Imaging (MRI) of brain showed characteristic radiological changes. Complete recovery was seen in 5 patients, with no evidence of recurrence on follow up. Considering such a myriad presentations, this entity should always be considered in differential diagnosis of acute encephalopathy. MRI should form a part of workup in all cases.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
